ライフサイエンスコーパス: transient ischemic attack

1 ds of periprocedural mortality and stroke or transient ischemic attack.

2 l ischemia during cardiac arrest or forms of transient ischemic attack.

3 s likely to be female or have a prior stroke/transient ischemic attack.

4 l death, myocardial infarction, or stroke or transient ischemic attack.

5 y in reducing disease burden after stroke or transient ischemic attack.

6 mic embolism, second only to prior stroke or transient ischemic attack.

7 ation (1995-1998) to risk of incident stroke/transient ischemic attack.

8 s one fatal intracerebral hemorrhage and one transient ischemic attack.

9 130 participants experienced incident stroke/transient ischemic attack.

10 Secondary outcome was stroke or transient ischemic attack.

11 re ultimately not diagnosed with a stroke or transient ischemic attack.

12 tic peripheral vascular disease, stroke, and transient ischemic attack.

13 ,940 participants without previous stroke or transient ischemic attack.

14 ents without a clinical history of stroke or transient ischemic attack.

15 dividuals evaluated after ischemic stroke or transient ischemic attack.

16 th insulin resistance and a recent stroke or transient ischemic attack.

17 ients who have had recent ischemic stroke or transient ischemic attack.

18 mellitus, after a recent ischemic stroke or transient ischemic attack.

19 t with rapidly resolving deficits resembling transient ischemic attacks.

20 .785; P=0.438) improved prediction of stroke/transient ischemic attacks.

21 y control subjects), and in 72 patients with transient ischemic attacks.

22 failure, 2 nonfatal myocardial infarction, 2 transient ischemic attack, 1 cardiovascular death).

23 eath rate: 1.2%; recurrent MI: 16.8%; stroke/transient ischemic attack: 1.2%; revascularization: 5.8%

24 e range), stroke 123.8 pmol/l (93 to 160.5); transient ischemic attack 114.5 pmol/l (85.3 to 138.8);

25 1.3%, respectively; P = .003), to have had a transient ischemic attack (12.5% vs 6.1%, respectively;

26 cerebrovascular event (stroke: 63 patients; transient ischemic attack: 12 patients) during the 3-yea

27 after 12- to 20-minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle,

28 Patients with adjudicated stroke (7) and transient ischemic attacks (19 in 11 standard/8 alternat

29 cept for a higher prevalence of prior stroke/transient ischemic attack (31.3% versus 26.1%, all P<0.0

30 There were 6 cases of stroke or transient ischemic attack (4 in the fibrinogen group); 4

31 hythmia, 8 nonfatal myocardial infarction, 5 transient ischemic attack, 5 heart failure, 2 nonfatal s

32 0.65-0.98; P=0.03) and with more strokes or transient ischemic attacks (55 [0.9%] versus 34 [0.5%];

33 n, 54%; diabetes mellitus, 30%; prior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%

34 00 patient-years), 46 (1.6%) had a stroke or transient ischemic attack (8.45/1000 patient-years), 19

35 CI, 2.2%-2.4%), and 373 patients (0.4%) with transient ischemic attacks (95% CI, 0.3%-0.4%) .

36 She had a transient ischemic attack about 4 years ago when she was

37 The combined risk of in-hospital stroke, transient ischemic attack, acute MI, or mortality was 19

38 There were 1075 stroke and transient ischemic attack admissions in the pretriage pe

39 ears, diabetes mellitus, and prior stroke or transient ischemic attack]), AF occurrence and duration,

40 In addition, 4 patients suffered transient ischemic attack after cardioversion.

41 s and characterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a

42 h CHADS(2) scores 4 to 6, previous stroke or transient ischemic attack, age >=75, and no previous cor

43 ctomies from patients with symptoms (stroke, transient ischemic attacks, amaurosis fugax) than in asy

44 h risk for stroke (311 prior ischemic stroke/transient ischemic attack and 153 prior hemorrhagic stro

45 llation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients

46 Outcome data on stroke/transient ischemic attack and bleeding complications dur

47 ere associated with increased risk of stroke/transient ischemic attack and improved risk prediction c

48 r, among patients with an ischemic stroke or transient ischemic attack and insulin resistance, those

49 ble to construct valid eQMs for processes of transient ischemic attack and minor ischemic stroke care

50 We sought to develop and validate transient ischemic attack and minor ischemic stroke elec

51 in 4,731 participants with recent stroke or transient ischemic attack and no known coronary heart di

52 hly effective strategy; however, the risk of transient ischemic attack and stroke is approximately 0.

53 SETTING, AND PARTICIPANTS: The Follow -Up of Transient Ischemic Attack and Stroke Patients and Uneluc

54 The rates of 30-day transient ischemic attack and stroke were assessed.

55 ht be the cause of clinical symptoms such as transient ischemic attack and stroke.

56 l of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclini

57 ata to evaluate care for their patients with transient ischemic attack and to complement and expand q

58 180 days of a qualifying ischemic stroke or transient ischemic attack and were followed for a maximu

59 er panel was associated with incident stroke/transient ischemic attack and with total cerebral brain

60 outcomes included thromboembolism or stroke/transient ischemic attacks and bleeding events.

61 ectrum of hypoperfusion disorders along with transient ischemic attacks and silent infarcts.

62 erapy for breast cancer have been related to transient ischemic attacks and stroke.

63 e substantially to morbidity associated with transient ischemic attacks and strokes (TIA-S).

64 r, diabetes mellitus, and previous stroke or transient ischemic attack) and CHA2DS2-VASc (congestive

65 romboembolism (stroke, systemic embolism, or transient ischemic attack) and major bleeding.

66 posite of myocardial infarction, stroke, and transient ischemic attack) and venous thromboembolism (V

67 hanged, 40,323 (23.2%) had a prior stroke or transient ischemic attack, and 112,174 (64.6%) had coron

68 of 67 subjects with ischemic stroke, 5 with transient ischemic attack, and 27 with ICH.

69 Geriatric Depression Scale >4, prior stroke/transient ischemic attack, and abnormal albumin received

70 ia or Latin America, older age, prior stroke/transient ischemic attack, and aspirin use at baseline.

71 rmined not to have suffered from a stroke or transient ischemic attack, and compared characteristics

72 gnificant effect on the composite of stroke, transient ischemic attack, and death in adjusted but not

73 adverse cardiac and cerebrovascular events, transient ischemic attack, and definitive ischemic brain

74 Cohort participants free of clinical stroke, transient ischemic attack, and dementia formed our sampl

75 angina, coronary revascularization, stroke, transient ischemic attack, and heart failure.

76 ement therapy, multiorgan failure, stroke or transient ischemic attack, and hemolysis.

77 etes, angina, myocardial infarction, stroke, transient ischemic attack, and kidney disease, patients

78 bserved incident CV event, including stroke, transient ischemic attack, and myocardial infarction (MI

79 Crude 30-day mortality, stroke or transient ischemic attack, and myocardial infarction ris

80 ssion for embolic (cerebrovascular accident, transient ischemic attack, and noncerebral arterial thro

81 fatal myocardial infarction, angina, stroke, transient ischemic attack, and peripheral artery disease

82 chemic stroke as well as unspecified stroke, transient ischemic attack, and pulmonary embolism) yield

83 e, first CeVD event (acute brain infarction, transient ischemic attack, and stroke-related death) alo

84 luding death, myocardial infarction, stroke, transient ischemic attack, and the composite outcome, de

85 ath, myocardial infarction, ischemic stroke, transient ischemic attack, and unstable angina.

86 eported; 76% were ischemic strokes (IS), 15% transient ischemic attacks, and 9% hemorrhagic strokes.

87 ascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic even

88 eases such as myocardial infarction, stroke, transient ischemic attacks, and pulmonary embolism are m

89 ent or angina, intermittent claudication, or transient ischemic attack; and (2) all-cause mortality.

90 nfarction/stroke/(severe) recurrent ischemia/transient ischemic attack/arterial thrombotic events, to

91 d long-term risks of mortality and stroke or transient ischemic attack, as well as periprocedural myo

92 There was no mortality, stroke, or transient ischemic attack at 1 year in either group.

93 Two patients, 1 from each group, presented transient ischemic attack at 3-month follow-up.

94 (risk of venous thromboembolism, stroke, or transient ischemic attack) at 3 months, no significant d

95 There were no instances of stroke, transient ischemic attack, atrioesophageal fistulas, or

96 Patients who have suffered a stroke or transient ischemic attack attributed to stenosis (50-99%

97 d, without bevacizumab because of the recent transient ischemic attack; carboplatin was selected over

98 tion on the occurrence of incident stroke or transient ischemic attack, cardiovascular events, and nu

99 Preprocedural neurologic symptoms included transient ischemic attack, cerebrovascular accident, and

100 s, diabetes mellitus, and previous stroke or transient ischemic attack (CHADS2) and Anticoagulation a

101 t 1 year, whereas patients with prior stroke/transient ischemic attack, chronic obstructive pulmonary

102 ically symptomatic disease (recent stroke or transient ischemic attack) compared to asymptomatic dise

103 Ipsilateral stroke or transient ischemic attack, death from ipsilateral stroke

104 predicted the risk of ipsilateral stroke or transient ischemic attack, death from stroke, or death f

105 ence of comorbidities including prior stroke/transient ischemic attack, diabetes, and coronary artery

106 Older age, prior hemorrhage, prior stroke or transient ischemic attack, diabetes, lower creatinine cl

107 ia-related ED visits resulted in a stroke or transient ischemic attack diagnosis.

108 imary end point was a composite of stroke or transient ischemic attack during 2 years of follow-up, d

109 adjusted hazards of mortality and stroke or transient ischemic attack during and after the periproce

110 e incidence and outcomes of acute stroke and transient ischemic attack during pregnancy or within 6 w

111 ith acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (P

112 spirin were age >/=75 years, prior stroke or transient ischemic attack, estimated glomerular filtrati

113 nd parameters performed similarly for stroke/transient ischemic attack event prediction.

114 nts with previous MI without prior stroke or transient ischemic attack for whom there is a clinical i

115 d to patients without a history of stroke or transient ischemic attack given its contraindication in

116 patients with cryptogenic ischemic stroke or transient ischemic attack has not been compared with tha

117 brillation patients with ischemic stroke and transient ischemic attack have not been well characteriz

118 of nonfatal coronary heart disease, stroke, transient ischemic attack, heart failure hospitalization

119 ibrillation patients with ischemic stroke or transient ischemic attack hospitalized between October 2

120 .07-1.31), hypertension HR 1.37 (1.29-1.45), transient ischemic attack HR 2.74 (2.41-3.12), atrial fi

121 The ABC-stroke (age, prior stroke/transient ischemic attack, hsTnT, NT-proBNP) and ABC-ble

122 The only thromboembolic complication was transient ischemic attack in 1 patient (0.2%; 95% confid

123 strokes, or operative mortality (<30 days), transient ischemic attack in 1 patient, reoperation for

124 Clinical strokes were detected in 17%, transient ischemic attack in 2%, and in-hospital mortali

125 ine clearance <60 mL/min and prior stroke or transient ischemic attack in a model with no other covar

126 The primary outcome event was stroke or transient ischemic attack in any territory occurring bet

127 hemorrhage in 71 patients (87.6%), stroke or transient ischemic attack in five patients (6.2%), and o

128 hs, stroke occurred in 2 patients on OAC and transient ischemic attack in one without OAC in the LAAI

129 as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibril

130 brovascular events consistent with stroke or transient ischemic attack in relation to mean radiograph

131 eparin-bridging group and one stroke and one transient ischemic attack in the continued-warfarin grou

132 s in acute stroke (ischemic and hemorrhagic)/transient ischemic attack incidence and in-hospital mort

133 diac arrest, to weak (hazard ratio <1.5) for transient ischemic attack, intracerebral hemorrhage, and

134 rdial infarction, pulmonary embolism, stroke/transient ischemic attack, intracranial bleeding or valv

135 han 1 year after an index ischemic stroke or transient ischemic attack is not associated with a great

136 -based guidelines for treatment of stroke or transient ischemic attack is suboptimal.

137 years with cerebrovascular events, including transient ischemic attack, ischemic and hemorrhagic stro

138 diabetes and for those with prior strokes or transient ischemic attacks, it has become evident that a

139 Being Hispanic and having had a transient ischemic attack-like episode were predictors o

140 vealed recurrent transient motor and sensory transient ischemic attack-like symptoms over the precedi

141 ruit (LR, 0.12; 95% CI, 0.03-0.47) and prior transient ischemic attack (LR, 0.34; 95% CI, 0.18-0.65).

142 stinguish recrudescence from mimics, such as transient ischemic attacks, migraine, Todd paralysis, an

143 ly associated with delirium: prior stroke or transient ischemic attack, Mini Mental State Examination

144 [4.8-fold; P=7.8x10(-9)]) and patients with transient ischemic attack (miR-125a-5p: P=0.003; miR-125

145 nd point was a composite of ischemic stroke, transient ischemic attack, myocardial infarction, or oth

146 neutropenia (n = 2), leukopenia (n = 1), and transient ischemic attack (n = 1).

147 e (n = 124; 65.6%) compared to patients with transient ischemic attack (n = 16; 8.5%) and to patients

148 ys (mRS = 1) (95% CI: 1.3%, 8.4%), including transient ischemic attack (n = 2), small cerebral infarc

149 n = 69), edema (n = 30), and previous stroke/transient ischemic attack (n = 21).

150 who reported a physician diagnosis of stroke/transient ischemic attack (n = 647) or stroke symptoms (

151 embolic events (3.7% strokes [n=29] and 1.3% transient ischemic attacks [n=10]) in group 1: two event

152 bacute stroke, n = 2; chronic stroke, n = 3; transient ischemic attack, n = 2) underwent 3D time-of-f

153 Transient ischemic attack occurred in 1 (1%) patient 2 d

154 Periprocedural stroke/transient ischemic attack occurred in 27 patients (1.1%)

155 Stroke or transient ischemic attack occurred in 66 (0.8%) randomiz

156 In the CAS group, recurrent stroke or transient ischemic attack occurred more often among DWI+

157 Cerebrovascular accidents/transient ischemic attacks occurred in 26 patients (13%)

158 in patient subgroups presenting with stroke, transient ischemic attack, ocular symptoms, and asymptom

159 fect was driven by a decrease in the risk of transient ischemic attack of 5% versus 14%, respectively

160 rs of mortality were remote (> or =6 months) transient ischemic attack or cerebrovascular accident, s

161 METHODS AND A random sample of patients with transient ischemic attack or minor ischemic stroke, care

162 mize benefit and reduce risk after high-risk transient ischemic attack or minor ischemic stroke.

163 xyglucose PET/CT in 26 patients after recent transient ischemic attack or minor ischemic stroke: 18 p

164 acute infarct or hemorrhage, no evidence of transient ischemic attack or seizure, no acute lesion on

165 ry (51% vs 32%, P < .001), or had history of transient ischemic attack or stroke (16% vs 10%, P < .00

166 Participants with recent VB transient ischemic attack or stroke and 50% or more athe

167 randomly assigned patients who had a recent transient ischemic attack or stroke attributed to stenos

168 In group 1, transient ischemic attack or stroke was the presenting s

169 ere assessed clinically for recent symptoms (transient ischemic attack or stroke) and divided equally

170 events were common: 19.2% of patients had a transient ischemic attack or stroke, 19.7% had experienc

171 e mortality, nonfatal myocardial infarction, transient ischemic attack or stroke, and heart failure r

172 cular events among patients with PFO-related transient ischemic attack or stroke.

173 er age were independent predictors of stroke/transient ischemic attack or systemic embolism.

174 s [2 points], diabetes mellitus, and stroke, transient ischemic attack or thromboembolism [2 points]-

175 ubled], type 1 or type 2 diabetes, stroke or transient ischemic attack or thromboembolism [doubled],

176 75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular d

177 nd subsequent vascular complications such as transient ischemic attacks or stroke.

178 ptomatic if symptoms consistent with stroke, transient ischemic attack, or amaurosis fugax had occurr

179 re asymptomatic (i.e., had not had a stroke, transient ischemic attack, or amaurosis fugax in the 180

180 ion for acute myocardial infarction, stroke, transient ischemic attack, or cardiovascular death.

181 The primary composite outcome was stroke, transient ischemic attack, or death; the secondary outco

182 Cohort participants free of clinical stroke, transient ischemic attack, or dementia (age, 61+/-9 year

183 ce of a composite of embolic events: stroke, transient ischemic attack, or extracranial systemic arte

184 nd point was a composite of ischemic stroke, transient ischemic attack, or peripheral embolism.

185 e primary outcome was a composite of stroke, transient ischemic attack, or peripheral embolism.

186 tion, coronary or carotid revascularization, transient ischemic attack, or stroke.

187 TE was defined as stroke, transient ischemic attack, or systemic embolism.

188 ed 4.7+/-0.8 cm; and 48% had a prior stroke, transient ischemic attack, or systemic embolism.

189 = 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism [doubled])

190 n, age, diabetes mellitus, and prior stroke, transient ischemic attack, or thromboembolism) score >/=

191 5 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular

192 ospital staff enrolled 6024 adult stroke and transient ischemic attack patients discharged home betwe

193 After an ischemic stroke or transient ischemic attack, patients at higher risk for s

194 dial infarction [MI], heart failure, stroke, transient ischemic attack, peripheral arterial complicat

195 h stroke scale score >0, prior stroke, prior transient ischemic attack, peripheral vascular disease,

196 d up from procedure date until death, stroke/transient ischemic attack, periprocedural myocardial inf

197 Patients with ischemic stroke or transient ischemic attack presumably related to patent f

198 le sex, higher body mass index, prior stroke/transient ischemic attack, prior systemic embolism, and

199 cardiovascular death and increased stroke or transient ischemic attack provide a rationale for future

200 rtality, congestive heart failure, stroke or transient ischemic attack, recurrent acute rheumatic fev

201 dial infarction, cerebrovascular accident or transient ischemic attack, renal insufficiency or failur

202 in 47 (7.3%) and 2 (0.3%) patients (both had transient ischemic attacks) respectively.

203 nsion, age>75, diabetes, and prior stroke or transient ischemic attack) risk (70.9% to 59.5% for CHAD

204 ears, diabetes mellitus, and prior stroke or transient ischemic attack) score >/=1, who were consider

205 ears, diabetes mellitus, and previous stroke/transient ischemic attack) score >/=2 or 1 and another r

206 ears, diabetes mellitus, and prior stroke or transient ischemic attack) score >2, no stroke/transient

207 75 years, diabetes mellitus, prior stroke or transient ischemic attack) score than men (1.99 [SD, 1.1

208 >75, Diabetes mellitus, and prior stroke or transient ischemic attack] score >/=2).

209 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) scores of 0 to 1, representin

210 ptide], and clinical history of prior stroke/transient ischemic attack)-stroke risk score and compare

211 The 30-day transient ischemic attack, stroke, and death rates were

212 ed emergency hospitalization for arrhythmia, transient ischemic attack, stroke, myocardial infarction

213 ents with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax),

214 ents with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax),

215 ation applies to adults without a history of transient ischemic attack, stroke, or other neurologic s

216 le range [IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic attack/stroke (median difference: 0.1

217 primary endpoint was the 30-day incidence of transient ischemic attack/stroke or new ischemic lesions

218 e clopidogrel also significantly reduced the transient ischemic attack/stroke rate at 30 days (0% vs.

219 The primary composite outcome was stroke, transient ischemic attack, systemic embolism, cardiovasc

220 death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thro

221 There was a similar number of stroke/transient ischemic attack/systemic embolic events (6 ver

222 14 days), and outcomes were recurrent stroke/transient ischemic attack/systemic embolism, symptomatic

223 ated in patients with a history of stroke or transient ischemic attack, the analysis (n=16 896) exclu

224 In participants with recent stroke or transient ischemic attack, the total number of vascular

225 f death, nonfatal coronary ischemia, stroke, transient ischemic attack, thromboembolism, or heart fai

226 age >/=75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vas

227 urrent ischaemic events were prior stroke or transient ischemic attack (TIA) (HR 1.42, 95% CI 0.96 to

228 Prior studies of stroke and transient ischemic attack (TIA) after transcatheter aort

229 We compared rates of stroke or transient ischemic attack (TIA) among patients using rhy

230 e who presented with a cryptogenic stroke or transient ischemic attack (TIA) and had a patent foramen

231 Rates of stroke/transient ischemic attack (TIA) and heart failure hospit

232 sclerotic plaque rupture is thought to cause transient ischemic attack (TIA) and ischemic stroke (IS)

233 Patients with transient ischemic attack (TIA) are at increased risk fo

234 Patients with ischemic stroke or transient ischemic attack (TIA) are at increased risk fo

235 tery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased

236 sterol values and who had no prior stroke or transient ischemic attack (TIA) at baseline.

237 Transient ischemic attack (TIA) can be difficult to diag

238 redictors of periprocedural stroke or stroke/transient ischemic attack (TIA) combined.

239 coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate o

240 e whether a PFO increases the risk of stroke/transient ischemic attack (TIA) in patients with endocar

241 remained on OAC, and the incidence of stroke/transient ischemic attack (TIA) in this population was 1

242 Transient ischemic attack (TIA) is defined as focal neur

243 currence after an initial ischemic stroke or transient ischemic attack (TIA) may be impacted by undia

244 s >/=55 years without a history of stroke or transient ischemic attack (TIA) of the Rotterdam Study,

245 12 to 20% during the first 3 months after a transient ischemic attack (TIA) or minor stroke.

246 rapy (DAPT) reduced stroke risk in high-risk transient ischemic attack (TIA) patients assessed by ABC

247 eedom from cerebrovascular accident (CVA) or transient ischemic attack (TIA), and 30-day mortality.

248 ) death, myocardial infarction (MI), stroke, transient ischemic attack (TIA), and major adverse cardi

249 prospective cohort study of prognosis after transient ischemic attack (TIA), ischemic stroke, or hem

250 d 724 consecutive patients with a first-ever transient ischemic attack (TIA), ischemic stroke, or int

251 CCE, which included a composite of stroke or transient ischemic attack (TIA), myocardial infarction,

252 a patent foramen ovale and ischemic stroke, transient ischemic attack (TIA), or a peripheral thrombo

253 6.5 days; interquartile range, 4-8) stroke, transient ischemic attack (TIA), or retinal embolism and

254 rence after a cryptogenic ischemic stroke or transient ischemic attack (TIA).

255 The primary outcome was ischemic stroke or transient ischemic attack (TIA).

256 cumented clinical chickenpox and a stroke or transient ischemic attack (TIA).

257 ute ischemic lesions and might help diagnose transient ischemic attack (TIA).

258 o prevent stroke after an ischemic stroke or transient ischemic attack (TIA).

259 ine care of patients with ischemic stroke or transient ischemic attack (TIA).

260 scular outcomes in acute ischemic stroke and transient ischemic attack (TIA).

261 platelet function in patients with stroke or transient ischemic attack (TIA).

262 te the morphology with the history of stroke/transient ischemic attack (TIA).

263 Symptom duration less than 24 h defines transient ischemic attack (TIA).

264 7 T in participants with ischemic stroke or transient ischemic attack (TIA).

265 ardiographic abnormalities, and incidence of transient ischemic attack (TIA)/stroke and myocardial is

266 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack [TIA], Vascular disease, Age 6

267 due to a cryptogenic embolism (stroke: 76%, transient ischemic attack [TIA]: 32%, systemic embolism:

268 Transient ischemic attacks (TIAs) are common and portend

269 and clinical outcomes (including strokes and transient ischemic attacks [TIAs]).

270 0 years or older with a history of stroke or transient ischemic attack to achieve a target systolic b

271 ants without clinical histories of stroke or transient ischemic attack underwent brain MRI in 1992 an

272 Three transient ischemic attacks, unrelated to DCCV, were foun

273 oration and tamponade, pneumothorax, stroke, transient ischemic attack, vascular access complications

274 rterial thromboembolic events, MI, stroke or transient ischemic attack, vascular deaths, and major va

275 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 ye

276 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 ye

277 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 ye

278 age >/= 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 7

279 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 7

280 , age >/=75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 7

281 ge >/=75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 7

282 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 7

283 ge >/=75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 7

284 Hypertension, Age 75 years, Diabetes, Stroke/transient ischemic attack, Vascular disease, Age 65 to 7

285 n, age >=75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 7

286 , age >/=75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 y

287 ension, age >/=75, diabetes, prior stroke or transient ischemic attack, vascular disease, age 65-74,

288 or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to

289 rtension, diabetes mellitus, previous stroke/transient ischemic attack, vascular diseases, chronic ki

290 h a history of stroke, systemic embolism, or transient ischemic attack was 39.4%/y versus 30.3%/y wit

291 Readmission due to a stroke or transient ischemic attack was more common among patients

292 ansient ischemic attack) score >2, no stroke/transient ischemic attack was reported in group 3.

293 ,390 patients without a history of stroke or transient ischemic attack were found in 201 patients wit

294 y heart disease (CHD) events, and 196 stroke/transient ischemic attacks were observed.

295 on, heart failure, diabetes, or prior stroke/transient ischemic attack) were randomized to either the

296 She initially presented after a transient ischemic attack, when a chest radiograph demon

297 30-day strokes (minor and major strokes and transient ischemic attacks) with TAVR (5.5% vs. 2.4%, p

298 icipants had a qualifying ischemic stroke or transient ischemic attack within 180 days of entry and i

299 and the primary safety outcome was stroke or transient ischemic attack within 30 days.

300 in 4 patients (0.3%): 2 ischemic strokes, 1 transient ischemic attack without residual deficit, and